Healthcare Sales & Marketing Network News: jaundice

Searching News Database: jaundice

HSMN NewsFeed - 30 Jun 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 15 Oct 2020
Titan Pharmaceuticals Provides a Strategic & Corporate Update
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Oct 2019
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Mar 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 14 Feb 2019
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Jul 2018
AbbVie Receives U.S. FDA Approval of ORILISSA(TM) (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Feb 2018
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 10 Nov 2016
Allergan Announces Launch of TAYTULLA(TM) (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules) 1 mg/20 mcg, the First and Only Oral Contraceptive Softgel Capsule
Biopharmaceuticals Product Launch

HSMN NewsFeed - 24 Oct 2016
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Mar 2016
Allergan Launches Bold Access To LILETTA(R) (levonorgestrel-releasing intrauterine system)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Apr 2015
Actavis and Medicines360 Announce U.S. Availability of LILETTA(TM) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
Biopharmaceuticals Product Launch

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Feb 2013
Pernix Therapeutics Receives FDA Approvals
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2012
Natus Comments on FDA Recall
Devices Product Recall FDA

HSMN NewsFeed - 20 Aug 2012
Reckitt Benckiser Pharmaceuticals Inc. Announces FDA Approval of Two New Dosage Strengths of Suboxone(R) Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence
Biopharmaceuticals FDA

HSMN NewsFeed - 31 May 2012
New Data Showed LIVALO(R) (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
Biopharmaceuticals Cardiology

HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 9 Nov 2011
Merck Launches NEXPLANON(R) (etonogestrel implant) 68 mg in the United States � A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 16 Sep 2011
Natus Acquires Embla Systems LLC - Leading Sleep Diagnostic Company
Devices Mergers & Acquisitions

HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Feb 2011
Natus Medical Appoints John T. Buhler as President and COO
Devices Personnel

HSMN NewsFeed - 8 Feb 2011
Pervasis Receives FDA Fast Track Status for Vascugel(R) to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Biopharmaceuticals Interventional FDA

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 4 Feb 2011
FDA Approves Makena, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2010
Natus Acquires Medix - Leading Newborn Care Company in Latin America
Devices Mergers & Acquisitions

HSMN NewsFeed - 22 Sep 2010
Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
Diagnostics FDA

HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 27 Jul 2010
Instrumentation Laboratory Receives FDA Clearance for New Automated Total Bilirubin Assay on GEM Premier 4000 Critical Care Analyzer
Diagnostics FDA

HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 13 Jan 2010
Natus Medical Announces Reorganization
Devices

HSMN NewsFeed - 14 Sep 2009
Natus Medical to Acquire Alpine Biomed
Devices Monitoring Neurology Mergers & Acquisitions

HSMN NewsFeed - 6 Jul 2009
Natus Medical Acquires Hawaii Medical
Devices Mergers & Acquisitions

HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals

HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Biopharmaceuticals

HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 8 Oct 2008
Natus Medical to Acquire Products from BrainZ Instruments Limited
Devices Monitoring Acquisitions

HSMN NewsFeed - 3 Sep 2008
Natus Medical to Acquire NeuroCom International
Devices Mergers & Acquisitions

HSMN NewsFeed - 25 Jul 2008
Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
Biopharmaceuticals Cardiology

HSMN NewsFeed - 2 Jul 2008
Natus Medical Acquires Schwarzer GmbH Neurology Division
Devices Neurology Acquisitions

HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 28 May 2008
Natus Medical Completes Acquisition of Sonamed
Devices Mergers & Acquisitions

HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Natus Medical to Acquire SonaMed
Devices Mergers & Acquisitions

HSMN NewsFeed - 24 Mar 2008
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2008
Natus Medical to Resume Domestic Shipments of Olympic Cool-Cap
Devices FDA Neurology

HSMN NewsFeed - 11 Feb 2008
Natus Medical Announces Integration and Restructuring
Devices

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals

HSMN NewsFeed - 27 Nov 2007
Natus Resumes Production and Shipping Operations at Olympic Facility
Devices

HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 10 Oct 2007
Natus Medical to Acquire Excel-Tech Ltd.
Devices Mergers & Acquisitions

HSMN NewsFeed - 17 Sep 2007
FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Biopharmaceuticals Urology FDA

HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 21 May 2007
BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology

HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2007
Natus Medical Signs Three-Year Supplier Contracts with Premier, Inc.
Devices Group Purchasing

HSMN NewsFeed - 14 Apr 2007
Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals

HSMN NewsFeed - 13 Apr 2007
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Biopharmaceuticals

HSMN NewsFeed - 2 Apr 2007
FDA Approves Accelerated Dosing Schedule for GlaxoSmithKline's Twinrix(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology

HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Dec 2006
Natus Medical Receives FDA Approval for the Olympic Cool-Cap
Devices FDA Neurology

HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2006
Natus Medical Announces Introduction of BioMAP Software for Navigator Pro AEP System
Devices

HSMN NewsFeed - 30 Oct 2006
Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2006
BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2006
Study Shows Treatment with BARACLUDE(R) (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 16 Oct 2006
InfaCare Pharmaceutical Appoints Dr. Ronald Dundore, Vice President of Regulatory and Quality Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Oct 2006
Natus Medical to Acquire Olympic Medical
Devices Mergers & Acquisitions

HSMN NewsFeed - 6 Oct 2006
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Oct 2006
Important safety information about KETEK (telithromycin)
Biopharmaceuticals

HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Sep 2006
Natus Medical to Acquire DELTAMED
Devices Mergers & Acquisitions

HSMN NewsFeed - 5 Sep 2006
Roche Requests Re-Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Aug 2006
FDA Expands REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown to Inhibit Joint Damage and Improve Physical Function
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jul 2006
European Union's CHMP Adopts Positive Opinion for SUBOXONE(R) (Buprenorphine/Naloxone) for Treatment of Opioid Dependence
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Jun 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jun 2006
FDA Accepts REMICADE(R) Supplemental Biologics License Application for Inhibition of Structural Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jun 2006
Alexion Announces the EXPLORE Clinical Diagnostic Study for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 May 2006
96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 4 Apr 2006
FDA Grants Priority Review of REMICADE(R) for the Treatment of Children with Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 23 Mar 2006
REMICADE(R) Is Approved in Australia for Treatment of Early Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Mar 2006
REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 6 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 3 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 30 Jan 2006
European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory

Return to NewsFeed

Additional items found! 73

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 73 additional stories matching:
jaundice
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.